Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy.
Part 4 of this study is currently enrolling.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Has a pre-existing condition that is contraindicated including.
History of other active malignancies, including myelodysplastic syndrome (MDS), within the past 3 years prior to study entry Other protocol defined inclusion/exclusion criteria could apply
Primary purpose
Allocation
Interventional model
Masking
120 participants in 1 patient group
There are currently no registered sites for this trial.
Central trial contact
ABBVIE CALL CENTER
Start date
Jan 19, 2017 • 7 years ago
Today
Dec 30, 2024
End date
Jun 22, 2027 • in 2 years
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal